Idenix Pharmaceuticals Inc

Type: Company
Name: Idenix Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.idenix.com/
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

Triple Combination Works in Cirrhotic Hepatitis C Patients

LONDON — An interferon-free triple-combination antiviral regimen is highly effective in people with hepatitis C genotype 1 and cirrhosis, according to a new study."Safe and effective regimens are needed for patients with cirrhosis," which remains difficult ... [Published General Medicine eJournal - Apr 14 2014]
First reported Apr 12 2014 - Updated Apr 12 2014 - 1 reports

AbbVie's '3D' Combination Successful in Hepatitis C

LONDON ― An interferon-free triple combination antiviral regimen was nearly universally effective in treating hepatitis C genotype 1–infected patients in 2 new phase 3 trials.AbbVie's combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), ... [Published Diabetes Care - Apr 12 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Idenix Pharmaceuticals, Inc.'s "Good" News Shows Hep C Drug Market Increasingly Murky For Investors

In the cutthroat hepatitis C drug market — the recent focus of a slew of biotechs, both big and small — investors seem to be increasingly unsure what constitutes good news. Case in point is Idenix Pharmaceuticals (Nasdaq: IDIX), which saw its stock rise ... [Published BioSpace - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

Pipeline Update from Idenix

Idenix Pharmaceuticals, Inc. ( IDIX ) announced that its nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (:HCV) infection. IDX21437 was well-tolerated in 44 patients infected ... [Published Yahoo! Finance - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Idenix news shows hep C drug market increasingly murky for investors

In the cutthroat hepatitis C drug market — the recent focus of a slew of biotechs, both big and small — investors seem to be increasingly unsure what constitutes good news.Case in point is Idenix Pharmaceuticals (Nasdaq: IDIX), which saw its stock rise ... [Published Business First of Buffalo - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 4 reports

Drug treatment optimism lifts Idenix

Continue reading belowIdenix Pharmaceuticals Inc. rose on optimism about IDX21437, its lead nucleotide prodrug treatment for hepatitis C. Based on this progress, the biopharmaceutical said it would initiate a combination trial of IDX21437 and the hepatitis ... [Published Boston Globe - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Why Idenix Pharmaceuticals, B&G Foods, and Petrobras Rose Today

Last week's memories of near-record closes for the Dow Jones Industrials faded further into the background Monday, as the Dow posted a decline of more than 1% amid growing concerns about the market's valuation. Even though more volatile sectors of the ... [Published Motley Fool - Apr 08 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Idenix Pharmaceuticals Shares Sinking Lower, Down 4.9%

Written on Tue, 03/25/2014 - 12:26pmBy Nick RussoIdenix Pharmaceuticals ( NASDAQ:IDIX ) is a company whose shares are active, trading 4.9% lower to $6.37. The Dow is up 0.3% to 16,324 and the S&P is currently trading fractionally higher to 1,859.Idenix ... [Published Comtex SmarTrend - Mar 25 2014]
First reported Mar 24 2014 - Updated Mar 25 2014 - 4 reports

Idenix to appeal Norway District Court decision in Gilead’s favor

CAMBRIDGE, Mass.—, a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it intends to file an appeal to challenge the Oslo, Norway District Court's decision in a ... [Published Drug Discovery News - Mar 25 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 96 reports

Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa

SOURCE Analysts ReviewEditor Note: For more information about this release, please scroll to bottom.NEW YORKToday, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics ... [Published CW Richmond WUPV - Mar 21 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 3 reports

Top Gainers under Review -- Research on Coeur Mining, Eagle Rock Energy Partners, Idenix Pharma, and WidePoint

PR NewswireLONDON, March 19, 2014LONDONOn Tuesday, March 18, 2014SOURCE Investor-Edge ... [Published Digital Journal - Mar 19 2014]
First reported Mar 18 2014 - Updated Mar 19 2014 - 2 reports

Trouble Ahead for Gilead and Sovaldi?

Atop ever-inflating sales estimates for Gilead Science 's ( NASDAQ: GILD     ) blockbuster Sovaldi, patent battles also continue to crop up. Late last week Idenix Pharmaceuticals ( NASDAQ: IDIX     ) added three more suits to the pile, filing in France, ... [Published Motley Fool Discussion Boards - Mar 18 2014]

Quotes

"Safe and effective regimens are needed for patients with cirrhosis" which remains difficult to cure, even in the era of direct-acting antiviral therapy, said investigator Fred Poordad, MD, vice president of academic and...
"We won’t have [head-to-head] comparison data, so probably costs will drive the choice" he added
...7 million. The hepatitis C drug maker is suing Gilead Sciences in Europe for patent infringement. The lawsuits allege that "Gilead infringes Idenix's recently granted, co-owned European patent EP 1 523 489 that covers 2'-methyl-2'-fluoro nucleosides for treating the hepatitis C virus."
"We welcome Michael as an instrumental addition to our Supervisory Board," said Hans Schikan, Prosensa's CEO. "Michael's extensive financial and transactional expertise will support the company significantly in our efforts to bring much-needed, life-saving treatments for rare genetic diseases to patients. His long-term tenure at Genzyme, one of the most successful companies in the rare disease space, will be invaluable as we continue developing therapies for boys with Duchenne muscular dystrophy and building our company."

More Content

All (201) | News (178) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (1) | Press Releases (19)
sort by: Date | Relevance
C-WORTHy: Novel therapies show promise in patie... [Published Orthopedics Today - 22 hours ago]
Triple Combination Works in Cirrhotic Hepatitis... [Published General Medicine eJournal - Apr 14 2014]
AbbVie's '3D' Combination Successful in Hepatit... [Published Diabetes Care - Apr 12 2014]
Ledipasvir and Sofosbuvir for Previously Treate... [Published New England Journal of Medicine - Apr 12 2014]
Recently Released Market Study: Hepatitis C - P... [Published SBWire - Apr 11 2014]
Idenix Pharmaceuticals Has Returned 11.7% Since... [Published Individual.com - Apr 11 2014]
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for... [Published New England Journal of Medicine - Apr 11 2014]
Treatment of HCV with ABT-450/r–Ombitasvir and ... [Published New England Journal of Medicine - Apr 11 2014]
Idenix Pharmaceuticals, Inc.'s "Good" News Show... [Published BioSpace - Apr 09 2014]
Pipeline Update from Idenix [Published Yahoo! Finance - Apr 08 2014]
Idenix news shows hep C drug market increasingl... [Published Business First of Buffalo - Apr 08 2014]
Biotech Stocks to Watch as Sector Sells Off [Published Minyanville - Apr 08 2014]
Morning Review on Top Gainers -- Research on Pe... [Published Nasdaq - Apr 08 2014]
LEXICON PHARMACEUTICALS : Morning Review on Top... [Published 4 Traders - Apr 08 2014]
Morning Review on Top Gainers -- Research on Pe... [Published Financial Services - Apr 08 2014]
Mid-Morning Market Update: Markets Mixed; A. Sc... [Published Benzinga.com - Apr 08 2014]
Idenix Pharmaceuticals Inc: Promising Clinical ... [Published Value Walk - Apr 08 2014]
Idera Pharmaceutical Up After Market; Big Moves... [Published Bidness Etc - Apr 08 2014]
Prosensa to Appoint Michael Wyzga to Supervisor... [Published Benzinga.com - Apr 08 2014]
Drug treatment optimism lifts Idenix [Published Boston Globe - Apr 08 2014]
Myriad Submits Premarket Approval to FDA for BR... [Published BioMedReports - Apr 08 2014]
X-tra Hot Momentum Stocks: Agios Pharmaceutical... [Published Galaxy Stocks - Apr 08 2014]
Why Idenix Pharmaceuticals, B&G Foods, and Petr... [Published Motley Fool - Apr 08 2014]
Not a Good Day for Wall Street [Published Individual.com - Apr 07 2014]
Sears Takes a Tumble Following Lands’ End IPO [Published Value Walk - Apr 07 2014]
Idenix Pharmaceuticals' CEO Presents at Promisi... [Published Seeking Alpha - Apr 07 2014]
Idenix Announces Promising Clinical Data and Co... [Published Virtual Strategy Magazine - Apr 07 2014]
Idenix Announces Promising Clinical Data and Co... [Published GlobeNewswire: Acquisitions News - Apr 07 2014]
Idenix Announces Promising Clinical Data and Co... [Published Benzinga.com - Apr 07 2014]
2014 Q1 Global Life Sciences Web Benchmark: The... [Published Prlog - Apr 02 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Celgene, Gilead and a Truckload of Patent Trouble [Published BARRONS.com Stocks To Watch Today - Mar 14 2014]
Shares of Gilead (GILD) and Celgene (CELG) have tumbled today after both companies revealed that they were facing patent pressures. For Gilead, Idenix Pharmaceuticals (IDIX) filed a patent-infringement lawsuit that appears to target Gilead’s Sovaldi (someone ...
Idenix announces decision by USPTO Patent Trial... [Published PBR - News - Jan 30 2014]
Idenix Pharmaceuticals has announced that the US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board issued a decision in the first patent interference proceeding (No. 105,871) concerning one of its patent applications (US patent application ...
Why Idenix Could Rise Even Higher, and Challeng... [Published 24/7 Wall St. - Nov 02 2013]
Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) was the biggest gainer of all listed stocks on Friday with a rally of 40%. Its trading volume of almost 9.2 million shares was almost eight-times the normal... ...
1

Press Releases

sort by: Date | Relevance
Morning Review on Top Gainers -- Research on Pe... [Published Financial Services - Apr 08 2014]
Idenix Announces Promising Clinical Data and Co... [Published GlobeNewswire: Acquisitions News - Apr 07 2014]
Idenix Announces Nucleotide Prodrug (IDX21437) ... [Published GlobeNewswire: Acquisitions News - Mar 24 2014]
Idenix Pharmaceuticals Intends to Appeal Norway... [Published GlobeNewswire: Advertising News - Mar 24 2014]
Lawsuits, Clinical Studies, Financial Results, ... [Published Financial Services - Mar 21 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.